Skip to main content

Table 1 Demographics, tumour characteristics, and treatment of patients with DCIS

From: Necessity of sentinel lymph node biopsy in ductal carcinoma in situ patients: a retrospective analysis

Characteristic

 

Patients (n = 307) (%)

Age, years

Median (range)

52 (21–82)

 ≤ 40

36 (11.7)

 > 40 and ≤ 60

201 (65.5)

 > 60

70 (22.8)

Preoperative characteristics

Tumour size, cm

 ≤ 2

155 (50.5)

 

 > 2 and ≤ 5

124 (40.4)

 

 > 5

28 (9.1)

Palpability

Non-palpable

234 (76.2)

 

Palpable

73 (23.8)

Mammographic calcification

Present

192 (62.5)

 

Absent

115 (37.5)

Ultrasonic mass

Present

198 (64.5)

 

Absent

109 (35.5)

Tumour location

Upper-outer

105 (34.2)

 

Upper-inner

50 (16.3)

Lower-outer

60 (19.5)

 

Lower-inner

65 (21.2)

 

Multicentric

27 (8.8)

Biopsy method

Core-needle biopsy

174 (56.7)

 

VABB

8 (2.6)

 

Excisional biopsy

125 (40.7)

Postoperative characteristics

Type of breast surgery

BCS

145 (47.2)

 

TM

162 (52.8)

Type of axillary surgery

None

105 (34.2)

 

SLNB only

198 (64.5)

 

SLNB and ALND

4 (1.3)

Upstaging to invasive cancer

Yes

59 (19.2)

No

248 (80.8)

Axillary lymph node metastasis

Positive

4 (1.3)

 

Negative

303 (98.7)

Permanent size of DCIS, cm

 ≤ 2

156 (50.8)

 

2–5

124 (40.4)

 

 > 5

27 (8.8)

Permanent T stage

pTis

248 (80.8)

 

pT1mic

5 (1.6)

 

pT1a–pT1c

51 (16.6)

 

pT2

3 (1.0)

Nuclear grade

Low

67 (21.8)

 

Intermediate

150 (48.9)

 

High

90 (29.3)

Comedo necrosis

Present

153 (49.8)

 

Absent

154 (50.2)

ER

Positive

241 (78.5)

 

Negative

66 (21.5)

PR

Positive

211 (68.7)

 

Negative

96 (31.3)

HER2

Negative

233 (75.9)

 

Positive

74 (24.1)

Ki-67

Low

181 (59.0)

 

High

126 (41.0)

Main type of DCIS

Cribriform

125 (40.7)

 

Comedo

145 (47.2)

 

Solid

37 (12.1)

  1. BCS breast-conserving surgery, DCIS ductal carcinoma in situ, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, PR progesterone receptor, SLNB sentinel lymph node biopsy, TM total mastectomy, VABB vacuum-assisted breast biopsy